These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 20739846)

  • 1. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y; Otsuka F;
    Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma.
    Scoggins CR; Bowen AL; Martin RC; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; Hagendoorn L; McMasters KM
    Arch Surg; 2010 Jul; 145(7):622-7. PubMed ID: 20644123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
    Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
    Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
    Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
    Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
    van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
    Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
    Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
    Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma in children and the use of sentinel lymph node biopsy.
    Bütter A; Hui T; Chapdelaine J; Beaunoyer M; Flageole H; Bouchard S
    J Pediatr Surg; 2005 May; 40(5):797-800. PubMed ID: 15937817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
    Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
    Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma.
    Scoggins CR; Ross MI; Reintgen DS; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Davidson BS; Sussman JJ; Edwards MJ; Martin RC; Lewis AM; Stromberg AJ; Conrad AJ; Hagendoorn L; Albrecht J; McMasters KM
    J Clin Oncol; 2006 Jun; 24(18):2849-57. PubMed ID: 16782924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
    van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
    Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
    Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.